have reported that CTLA-4 blockade derives Treg cell destabilization only under low-glycolytic conditions,44 consistent with our finding that anti-CTLA-4 therapy is ineffective for ACVR2A-KO HCC (Figure S15F). The gene discussed is ACVR2A; the disease is hepatocellular carcinoma.